Previous studies indicated that most Type Ia ALPS patients carry heterozygous Fas mutations, and that the mutated Fas molecules have dominant interfering effects on the ability of normal Fas molecules to initiate apoptosis [4]. This evidence concerns the gene FAS and autoimmune lymphoproliferative syndrome.